Actively Recruiting
Phase 2 Study of Pembrolizumab with or without Chemotherapy Plus Additional Treatments for Untreated Stage IV Non-Small Cell Lung Cancer
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-16
90
Participants Needed
41
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating new treatments for advanced non-small cell lung cancer NSCLC that has not been treated before and has spread beyond what surgery can remove. The study focuses on combining pembrolizumab, an immunotherapy, with or without chemotherapy, alongside other treatments including the antibody-drug conjugate HER3-DXd. The main goals are to assess how safe and effective these treatment combinations are for participants with stage IV NSCLC. Participants will receive pembrolizumab as an intravenous infusion every three weeks for up to two years. One study group will also receive standard platinum-based chemotherapy regimens tailored to their cancer type, while another group will receive the HER3-DXd antibody-drug conjugate infusion alongside pembrolizumab. Chemotherapy drugs like paclitaxel, nab-paclitaxel, carboplatin, and pemetrexed are given according to specific schedules and doses, with treatment continuing until certain stopping criteria are met. During the study, participants will undergo regular assessments to monitor treatment response and side effects over up to five years. Researchers will measure overall response rates, adverse events, and treatment discontinuation due to side effects. Secondary measures include duration of response, progression-free survival, and overall survival. The trial includes safety monitoring and long-term follow-up, with participants attending scheduled visits for evaluations and infusions throughout the study period.
CONDITIONS
Brief Title
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here